Annual Report 2017 amfAR,The Foundation for AIDS Research Cover photo: A dendritic cell interacting with a T cell © Meletios Verras | Dreamstime.com Awards Contents

amfAR in 2017 01

Grants, Fellowships, and Awards 07

Research Grants, Fellowships, and Awards

TREAT Asia Grants and Awards

GMT Initiative Awards

Public Policy Awards

Financial Highlights 13

Leadership and Advisory Committees 15

Board of Trustees

Scientific Advisory Committee

Program Advisory Council

Management Group

amfAR, The Foundation for AIDS Research, is dedicated to ending the global AIDS epidemic through innovative research. HIGHLIGHTS amfAR CEO Kevin Robert Frost (right) moderates a panel discussion at the amfAR HIV Cure Summit.

Research u ARCHE, the amfAR Research Consortium on HIV Eradication, was launched in 2010. It supports collaborative teams of Countdown to a Cure for AIDS scientists in the U.S. and around the world working on a range of HIV cure strategies. In 2015, amfAR announced a $100 million investment strategy to support its Countdown to a Cure for AIDS initiative, which is aimed u The Opportunity Fund is a funding mechanism that enables at developing the scientific basis for a cure by 2020. The strategy amfAR to respond quickly to emerging and unforeseen research represents an unprecedented expansion of amfAR’s grant making opportunities. and is designed to provide support to any scientist or team of investigators for any research idea with the potential to advance the search for a cure, at any stage of its development. HIV Cure Summit amfAR has since awarded 58 Countdown grants totaling more than In December 2016, amfAR held its third annual HIV Cure Summit $41 million to support research conducted by 222 scientists working at UCSF. Leading amfAR-funded cure researchers detailed their at 74 institutions in 10 countries. Structured to provide sustained progress and discussed the scientific challenges that continue to support for a wide range of studies that advance both emerging and stand in the way of a cure. Drs. Peter Hunt, Warner Greene, Satish established ideas, the strategy comprises the following components: Pillai, and Steve Deeks reported on their efforts to pinpoint and measure the size of latent HIV u The amfAR Institute for HIV Cure Research, established in reservoirs; shock the virus 2016 with a $20 million grant over five years to the University of out of hiding so it can be California, San Francisco (UCSF), is the cornerstone of amfAR’s killed; and test interventions cure research efforts. developed by Institute u Innovation Grants, two-year awards of up to $200,000 each, researchers in clinical trials. enable researchers to test innovative ideas supported by limited preliminary data. Innovation Grants u Impact Grants of up to $2 million each over four years support In July 2017, amfAR awarded the in-depth development of concepts already underpinned by $1.2 million in Innovation preliminary data showing genuine potential for achieving a cure. grants to six researchers exploring mechanisms of u Investment Grants are aimed at recruiting the experience and HIV persistence and the expertise of scientists from outside the field of HIV. These $1 potential for viral eradication. million grants are awarded over a four-year period. Grantees Among the grantees were Dr. may have expertise in fields such as cancer, neuroscience, or amfAR grantee Dr. Benjamin Burwitz of Joshua Schiffer, from Fred inflammatory disease that can directly inform efforts to cure HIV. Oregon Health and Science University Hutchinson Cancer Research

1 Center in Seattle, who is testing a drug normally used to prevent Mathilde Krim Fellowships organ transplant rejection for its potential to eliminate the reservoir completely; Drs. Andrew Henderson, from Boston University School In October 2016, amfAR announced the recipients of the Mathilde of Medicine, and Fabio Romerio, from the University of Maryland in Krim Fellowships in Basic Biomedical Research, which support Baltimore, who are exploring a cure strategy known as “block and bright young scientists seeking innovative solutions to HIV/AIDS. lock,” which aims to silence HIV and prevent its re-emergence when The six Krim Fellows were each awarded approximately $150,000 therapy is stopped; and Dr. Benjamin Burwitz, from Oregon Health over two years. and Science University in Portland, who plans to generate a monkey model lacking the protein CCR5, the primary means by which most Published Research types of HIV infect cells. Research studies make the greatest impact on the HIV field and on the broader scientific community when they are published in Investment Grants scientific journals. In FY2017, 52 scientific publications resulted from In February 2017, amfAR announced a new round of Investment amfAR-funded research. grants totaling $1.2 million to support six research projects that enlist the help of bioengineers to eradicate the main barrier to a Think Tanks cure: latent HIV reservoirs. One pair of researchers—Dr. Timothy Henrich, of UCSF and the amfAR Institute for HIV Cure Research, In October 2016, amfAR hosted a think tank in Lisbon, Portugal, and bioengineer Dr. Utkan Demirci from Stanford—aim to apply titled, “Progress Report: Research toward a Cure for AIDS in magnetic levitation of single cells to identify and characterize HIV the context of IciStem.” IciStem is a consortium of 17 European reservoirs. Another team—Drs. Hui Zhang and Weiming Yang of researchers that aims to replicate the case of “the Berlin patient,” Johns Hopkins University in Baltimore—is using mass spectrometry who remains the only person known to have been cured of HIV. It to identify molecules on the surface of cells that differentiate latent was created and is funded by amfAR through its Countdown to a reservoirs from uninfected cells. And a third—Drs. Priti Kumar and Cure for AIDS initiative. Mark Saltzman of Yale University in New Haven, CT—is exploring a amfAR hosted another think tank in April 2017 in Palo Alto, CA, novel gene-editing approach using a cell’s machinery to eliminate on strategies to identify latently infected cells. The researchers HIV reservoirs. discussed finding a biomarker for these cells as an alternative approach to “shock and kill.” One of the biggest challenges with the “shock-and-kill” strategy is that current drug regimens do not reawaken all of the infected cells.

HIV Research Summit in Brazil

In March 2017, amfAR hosted an HIV research summit at the University of São Paulo, bringing together 250 community members, medical students, healthcare professionals, and representatives from 10 São Paulo-based nongovernmental organizations. The summit was held in conjunction with the Advanced Course on HIV Pathogenesis at the university’s School of Medicine.

TREAT Asia amfAR grantee Dr. Weiming Yang of Johns Hopkins University amfAR’s TREAT Asia (Therapeutics Research, Education, and AIDS

Training in Asia) program is a network of hospitals, clinics, and ARCHE (amfAR Research Consortium research institutions working with civil society to ensure the safe and on HIV Eradication) effective delivery of treatments for HIV and its co-infections to adults In July 2017, amfAR awarded more than $2.3 million in ARCHE and children across the Asia-Pacific through research, education, grants to seven teams of researchers (see page 7) working on gene and advocacy of evidence-based HIV-related policies. The TREAT therapy-based approaches to curing HIV. The researchers are Asia Network encompasses 21 adult and 20 pediatric sites pursuing projects such as: designing and refining vectors that can throughout the region, which collaborate on a variety of projects. accurately target HIV reservoir cells; using CAR T cells, which have TREAT Asia scientists produced a record 35 publications in peer- shown remarkable promise in curing cancer, to kill HIV-infected reviewed medical journals in 2017. cells; and using viral and non-viral delivery mechanisms to deliver genetic scissors to cut the virus out of human DNA.

2 Gathering Critical Information region and developing trainings for pediatric HIV providers. TREAT Asia hosted the first such training in June 2017 in Bangkok TREAT Asia pioneered the region’s first adult observational to help clinicians better diagnose and manage mental health database for HIV/AIDS—the TREAT Asia HIV Observational disorders in adolescents living with HIV. The workshop included Database (TAHOD)—which now includes anonymous data from more than 30 clinical and mental health professionals who work approximately 9,200 patients at 21 clinical sites in 12 countries. The with HIV-positive youth in Thailand, Cambodia, Indonesia, and information gathered in the database informs the development of Malaysia. Participants reviewed the epidemiology of adolescent more effective research and treatment programs and helps define mental health issues and discussed mental health needs among treatment standards specific to HIV/AIDS in Asia. The TAHOD youth living with HIV, psychopharmacology, and suicide risk Low-Intensity Transfer (TAHOD-LITE) database, an extension of assessment tools. TAHOD, contains data from over 37,000 HIV-positive patients across 10 TREAT Asia network sites. It aims to increase the scope of adult data collection by gathering a subset of core variables from Empowering Youth Advocates the entire cohort of HIV-infected patients who have sought care at The first class of TREAT Asia’s Youth ACATA—Asia Community selected TAHOD sites. for AIDS Treatment and Advocacy—held its final workshop in June 2017 in Bangkok, where eight young people living with HIV from A Global Collaboration Cambodia, Indonesia, and Thailand graduated from the two-year leadership training program. Launched in 2015 with support from Since 2006, TREAT Asia has managed the Asia-Pacific section of ViiV Healthcare’s Positive Action for Adolescents program, Youth the International epidemiology Databases to Evaluate AIDS (IeDEA), ACATA aims to educate participants about HIV and antiretroviral a global collaboration established by the U.S. National Institute of therapy and connect them to other HIV-positive youth in the region. Allergy and Infectious Diseases. In FY2017, the IeDEA consortium funded the second year of STAY (Study of Transitioning Asian Youth), which aims to document the experience of HIV-infected Helping Adolescents Transition to Adult Care young adults transitioning from pediatric to adult care. TREAT Asia continued working to help adolescents living with HIV transition to adult care. With funding from AIDS Life Austria, the Improving Care for Children program provided a grant to the Children and Youth Program of SEARCH (South East Asia Research Collaboration on HIV) at the The TREAT Asia Pediatric HIV Observational Database (TApHOD) is Thai Red Cross AIDS Research Centre in Bangkok to implement a regional pediatric HIV study set up by TREAT Asia in 2006. It was a transition model that focuses on issues such as moving to adult modeled after the adult database and includes data from more than care, coping with negative emotions, treatment, and stigma. 6,400 children and adolescents at 19 clinical sites in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam. Advocating for Co-Infection Treatment Access

Addressing Adolescent Mental Health In June 2017, TREAT Asia held its annual regional advocacy meeting on hepatitis C, HIV, and tuberculosis treatment in Bangkok, In January 2017, TREAT Asia organized a think tank in Bangkok on with civil society organizations, clinical care professionals, and adolescent mental health, bringing together regional investigators intellectual property experts. During the year, TREAT Asia also and youth advocates from Cambodia, Indonesia, Malaysia, Thailand, attended and presented at several conferences on hepatitis C and Vietnam to discuss gaps in research and clinical training. As a treatment access and partnered with civil society groups and result of the discussion, TREAT Asia is evaluating the prevalence funders on advocacy efforts. of mental health disorders among HIV-positive adolescents in the Introducing PrEP to the Philippines

Enrollment began in July 2017 for a two-year pilot project that introduced antiretroviral pre-exposure prophylaxis (PrEP) to the Philippines in an effort to curb the rapid spread of HIV infection among men who have sex with men (MSM) and transgender individuals. The project, known as PrEPPY (PrEP Pilipinas), is evaluating community-based, peer-driven delivery of PrEP at two clinics in Manila. amfAR is among several organizations involved in Project PrEPPY, a multiagency collaboration with experts from government, academia, and multilateral and nongovernmental organizations.

Special Reports

Volunteers at the Love Yourself organization, which is co-leading “Project In September 2017, TREAT Asia created the first in a series of PrEPPY” in the Philippines infographics titled Why Has Asia Fallen Behind on HIV/AIDS? to illustrate the stagnation in HIV program coverage in the 3 Asia-Pacific, “Making AIDS History: A Roadmap for Ending the Epidemic.” The Why Has Asia Fallen Behind and to remind conference highlighted the latest advances in HIV prevention, on HIV/AIDS? governments, civil treatment, and research and addressed the challenges that remain

Our global successes in reaching nearly 20 million people with antiretroviral treatment society, and donors in eradicating the virus. Speakers and panelists discussed the (ART) reflect the impact of programs such as the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund that much more national security implications of epidemics, the economic and health to Fight AIDS, Tuberculosis and Malaria. These programs have invested billions of dollars in HIV/AIDS treatment and prevention needs to be done impact of aging with HIV, and the opioid crisis and its relationship to in the hardest hit countries, many of which are in East and Southern Africa. to bring HIV/AIDS HIV and other infectious diseases. However, it is increasingly clear that the Asia-Pacific region has fallen behind Africa in its HIV/AIDS response, and that children, under control in women, and men in the Asia-Pacific have less access to lifesaving treatment and prevention interventions. the region. The stagnation we see in HIV program HIV and the Opioid Epidemic coverage in the Asia-Pacific is a reminder to governments, civil society, and donors that much more needs to be done to bring In conjunction with HIV/AIDS under control in the region. Also in June 2017, amfAR launched a comprehensive online amfAR’s Public database to help communities, policymakers, and advocates Policy Office, in effectively respond to the opioid epidemic. The Opioid & Health November 2016, Indicators Database (opioid.amfar.org) provides local and national East & Southern Africa Asia-Pacific TREAT Asia Treatment Treatment Prevention of statistics on HIV and hepatitis C infections, opioid use, overdose coverage, coverage, mother-to-child produced a report adults children transmission % of HIV+ adults % of HIV+ children % of pregnant women death rates, and the availability of services such as drug treatment aged 15+ aged <15 receiving ART titled Cervical to prevent HIV infection in their babies and syringe services programs. The Foundation also published an Cancer, Human issue brief outlining the case for supervised consumption services Sources: 2016 data from UNAIDS (aidsinfo.unaids.org) and WHO South East Asia Papillomavirus and Western Pacific Regional Offices (SCS), which provide a hygienic space for people to use illicit drugs (HPV), and HPV under the supervision of trained staff. The first in a series of three infographics Vaccines in showing the need for greater progress on Southeast Asia: HIV/AIDS in the Asia-Pacific region Key Considerations for Expanding Vaccine Coverage and Improving Population Health. The report documents the slow uptake of HPV vaccination in the region and gives recommendations for increasing use of the vaccine. Also with the Public Policy Office, in March 2017, TREAT Asia published the fact sheet PrEP Acceptability Among Female Sex Workers in Thailand: Key Research Findings, based on a study jointly conducted by the Institute for Population and Social Research at Mahidol University in Bangkok, Johns Hopkins Bloomberg School of Public Health in Baltimore, and the community-based organization Service Workers in Group (SWING) Foundation. amfAR’s Opioid & Health Indicators database is a comprehensive and invaluable resource for communities, lawmakers, and advocates. Public Policy Global Health Informed by thorough research and analysis, amfAR is a highly In January 2017, amfAR published a report arguing that a cure alone respected advocate of rational and compassionate AIDS-related will not end the HIV epidemic, and that only with a coordinated public policy. Through its Public Policy Office in Washington, DC, and enduring commitment can any disease be controlled. Using amfAR educates policymakers, the media, and the public about tuberculosis and malaria as examples, How Cures Can Fail shows evidence-based policies to address HIV/AIDS in the U.S. and around that global efforts to eradicate widespread diseases can fail even the world. when effective cures are available.

In June 2017, amfAR published Derailing Progress: The Human Ending the Domestic HIV Epidemic Impact of the U.S. FY2018 Global Health Budget, an infographic In October 2016, amfAR published a report that recommends showing the impact of $800 million in proposed cuts to the U.S. several measures health plans and healthcare purchasers can take President’s Emergency Plan for AIDS Relief (PEPFAR) and USAID in to help end the domestic HIV epidemic. Curbing the HIV Epidemic fiscal year 2018, a 17% decrease. Such a substantial reduction in by Supporting Effective Engagement in HIV Care: Recommendations funding could cause more than a million HIV treatment disruptions for Health Plans and Health Care Purchasers outlines actionable for both children and adults, new HIV infections, and 146,000 steps to improve health outcomes, reduce unnecessary spending, preventable AIDS-related deaths. and contribute to the development of more integrated systems of amfAR also published an issue brief outlining the potential impact of care for people living with HIV. President Trump’s action reinstating and expanding the Mexico City Policy. The policy has historically prohibited U.S. family planning Capitol Hill Briefing funding for non-U.S. nongovernmental organizations performing or promoting abortion. In June 2017, government officials, scientists, and public health leaders convened at an amfAR Capitol Hill conference titled, 4 In the News

In March 2017, amfAR Senior Policy and Medical Advisor Dr. Susan Blumenthal penned an op-ed for National Women and Girls HIV/AIDS Awareness Day warning of the implications of repealing the Affordable Care Act and limiting access to healthcare. The op-ed was published online on The Advocate and HuffPost.

In June 2017, Greg Millett, amfAR’s vice president and director of public policy, was widely quoted in a New York Times Magazine article titled “America’s Hidden H.I.V. Epidemic: Why do America’s black gay and bisexual men have a higher H.I.V. rate than any country in the world?” The piece focused on Jackson, MS, which has the nation’s highest rate of gay and bisexual men (40%) living with HIV.

Also in June, amfAR policy associate Alana Sharp and Dr. Rahul Gupta, public health commissioner and state health officer for West University of Pittsburgh/amfAR HIV Scholars (left to right): Daniel Dutra Virginia, published an opinion piece in The Hill on the impact of de Barros, Dr. Antonio Spagnolo, Kabelo Maleke, Adi Nugroho proposed cuts to the CDC and Medicaid affecting efforts to combat the opioid epidemic. West Virginia has the highest drug-related u And in Bangkok, Thailand, Dr. Nittaya Phanuphak and her team death rate in the country. at the Thai Red Cross AIDS Research Centre are working to show how innovative technologies such as GMT-targeted websites The GMT Initiative using online counseling and support can be utilized to increase rates of HIV testing and referrals to prevention and treatment Since 2007, amfAR has been serving the HIV-related needs of gay programs. men, other men who have sex with men (MSM), and transgender individuals (collectively, GMT) throughout the developing world through its GMT Initiative. Through small, targeted grants to amfAR HIV Scholars Program grassroots groups, amfAR has expanded access to HIV education and prevention services; supported advocacy aimed at increasing In December 2016, amfAR and the University of Pittsburgh funding for prevention and treatment services; and worked to end produced a supplement to the journal AIDS and Behavior devoted to the stigma, discrimination, and violence that threaten the lives of the HIV Scholars Program at the university’s Center for LGBT Health GMT and fuel the spread of HIV/AIDS. Research. The program’s mission is to support the creation of public health responses to dramatic HIV health disparities among GMT in low- and middle-income countries. The amfAR-funded program has Implementation Science Awards supported research training for 16 young investigators from a wide In FY2017, amfAR’s grant making through the GMT Initiative range of countries, including Pakistan, China, Lebanon, and Belize, evolved to support larger implementation science projects aimed at among others. identifying barriers to HIV testing, treatment, and care and studying In FY2017, amfAR supported four young HIV Scholars from the impact of innovative HIV service delivery models for GMT in low- Paraguay, Brazil, South Africa, and Indonesia undergoing five and middle-income countries. amfAR has awarded $2.6 million over months of graduate-level public health study at the Center for LGBT three years to support three such studies. Health Research at the University of Pittsburgh Graduate School of u Dr. Chris Beyrer of Johns Hopkins University is leading a team Public Health. The current HIV Scholars are Dr. Antonio Spagnolo of researchers and community-based services (in collaboration of the National University of Asunción in Paraguay; Daniel Dutra de with the International HIV/AIDS Alliance Myanmar) in evaluating Barros of Santa Casa de São Paulo School of Medical Sciences the effectiveness of promising interventions for GMT in Myanmar, in Brazil; Kabelo Maleke of Project Boithato at the Anova Health where increased HIV testing and treatment opportunities Institute in rural South Africa; and Adi Nugroho of the GWL-INA are becoming available. The researchers are assessing the Network in Jakarta, Indonesia. effectiveness of HIV self-testing done in the privacy of one’s home, point-of-care CD4 testing, and the use of “peer navigators” Public Information familiar with the local health system to help newly diagnosed individuals gain access to HIV treatment and care.. amfAR disseminates information on important HIV-related research, treatment, prevention, and policy issues for diverse audiences, u In Lima, Peru, Dr. Javier Lama of Asociación Civil Impacta Salud increasing awareness and knowledge of the pandemic. amfAR y Educación and his team are aiming to improve the continuum publishes a wide range of educational materials, maintains an of care among transgender women by using an innovative model informative website, and engages respected public figures, that integrates HIV prevention and treatment services with scientists, and policymakers in communicating the need for transgender-affirming medical care. continued research on HIV/AIDS.

5 Educational Materials from events, and posts images on Instagram from fundraising and program events. amfAR has 74,000 likes on Facebook, 43,000 amfAR produces a range of periodicals in both print and electronic Twitter followers, and more than 130,000 Instagram followers. formats, including its newsletter Innovations, published twice a year and distributed to more than 40,000 people; the TREAT Asia Report, an email newsletter distributed six times a year to more than 4,000 Media Outreach readers in the international health community; and a monthly e-mail In FY2017, amfAR continued to work closely with the media to raise newsletter distributed to nearly 70,000 people. The Foundation’s the profile of HIV/AIDS, both domestically and internationally, and websites—www.amfar.org and www.curecountdown.org—feature to help ensure the accuracy of HIV-related press coverage. Articles news, interviews, and original articles covering HIV research, policy, and reports involving amfAR—many of which included interviews the global epidemic, and amfAR programs and activities. The with staff—were carried in numerous media outlets, including The websites attract a combined average of 45,000 visitors per month. New York Times, The Washington Post, the Chicago Tribune, The amfAR also creates and distributes reports, press releases, and Hill, Politico, NBC News, CBS News, CNBC, U.S. News & World updates on major HIV/AIDS issues and conducts public service Report, Reuters, Ebony, and HuffPost. advertising campaigns that have been instrumental in educating policymakers, healthcare professionals, people living with HIV/AIDS, and the public. Celebrity Support

amfAR’s public awareness efforts are greatly enhanced by the Epic Voices committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the In June 2017, amfAR launched Epic Voices, an online video series Foundation’s mission. Support of amfAR by prominent public figures that aims to reenergize the response to HIV among millennial and began with the late Dame Elizabeth Taylor, amfAR’s Founding LGBTQ communities. The goals of the campaign are to renew International Chairman, and many have followed in her footsteps. awareness of the persistent threat of HIV, underscore the urgent need to support HIV research, and support amfAR’s leadership in Other celebrity supporters includeamfAR’s amfAR Epic Voices Ambassadors debuted in June Milla 2017, with the personal—and often inspirational—stories of five people the search for a cure. For the series, amfAR has spoken with HIV Jovovich, Michelle Yeoh, Cheyenneliving with Jackson, HIV who discuss and Lizahow the Minnelli, virus has a ected activists across the country, asking them to share their unique as well as Charlize Theron, Adrientheir lives Brody, and what Jessica a cure wouldChastain, mean for Matt them. The online video series aims to inspire millennials and LGBT journeys, their insights on living with HIV, and the bold steps they Bomer, Dita Von Teese, Gwynethcommunities Paltrow, to support Diana HIV/AIDS Ross, researchChiara and amfAR’s have taken in the fight against the epidemic. Ferragni, Diane Kruger, Iman, missionKatie Holmes,to find a cure. Uma Thurman, Kate Moss, Zac Posen, Zoe Saldana, Tobey Maguire, Dame Helen Mirren, Lea Michele, Michelle Rodriguez, Will Smith, Nicole Kidman, Social Media Naomi Campbell, Heidi Klum, Jon Hamm, Eva Longoria, Leonardo amfAR continues to expand its presence in the social media arena, DiCaprio, Robert De Niro, Nicki Minaj, Andrea Bocelli, Dean and Dan amfAR’samfAR’s Epic Epic Voices Voices debuted debuted in inJune June 2017, 2017, with with the the amfAR’samfAR’s Epic Epic Voices Voices debuted debuted in in June June 2017, 2017, with with the the reaching largepersonal—and personal—andnumbers ofoften often people, inspirational—stories inspirational—stories including aof of youngerfive five people people demographic Caten, Chris Tucker, Jennifer Garner, Scarlett Johansson, Donatella personal—andpersonal—and often often inspirational—stories inspirational—stories of of five five people people livingliving with with HIV HIV who who discuss discuss how how the the virus virus has has a ected a ected Versace, Victoria Justice, and Carine Roitfeld. that is often less educated about HIV and the AIDS epidemic.livingliving withThe with HIV HIV who who discuss discuss how how the the virus virus has has a ected a ected theirtheir lives lives and and what what a acure cure would would mean mean for for them. them. The The amfAR’s Epic Voices debuted in June 2017, with the theirtheir lives lives and and what what a acure cure would wouldpersonal—and mean mean for oftenfor them. them. inspirational—stories The The of five people “ Finding a cure for HIV means freedom. “ I feel like we’re on the precipice. The cure is the next step. Foundation regularlyonlineonline video video adds series series content aims aims to to inspire toinspire its millennials millennialsFacebook and and LGBTpage, LGBT live tweets onlineonline video video series series aims aims to to inspire inspireliving with millennials millennials HIV who discuss and and LGBT howLGBT the virus has a ectedFreedom from the stigma. Freedom from the virus. ” I want to be there to celebrate with everybody else. ” communitiescommunities to to support support HIV/AIDS HIV/AIDS research research and and amfAR’s amfAR’s communitiescommunities to to support support HIV/AIDS HIV/AIDStheir lives research research and what and anda cure amfAR’s amfAR’s would mean for them. The ONGINA KEN WILLIAMS missionmission to to find find a acure. cure. online video series aims to inspire millennials and LGBTDrag performer, HIV/AIDS and trans rights advocate, Los Angeles Public speaker, AIDS activist, founder of award-winning video blog “Ken Like Barbie,” Houston missionmission to to find find a acure. cure. communities to support HIV/AIDS research and amfAR’s mission to find a cure.

amfAR’s Epic Epic Voices Voices debuted debuted in June 2017, in June with the 2017, with the personal—and often often inspirational—stories inspirational—stories of five people of five people living with HIV who discuss how the virus has a ected living with HIV who discuss how the virus has a ected their lives and what a cure would mean for them. The “ Finding a cure for HIV means freedom. “ I feel like we’re on the precipice. The cure is the next step. FindingFinding a cure a cure for forHIV HIV means means freedom. freedom. “ I feel“ I feel like like we’re we’re on onthe the precipice. precipice. The The cure cure is the is the next next step. step. “ It’s time to end this. It’s time to bring a cure, to “ I was almost caught o guard. Someone’s still working on a cure! “ “ Freedom from the stigma. Freedom from the virus. I want to be there to celebrate with everybody else. ” “ FindingFinding a cure a cure for for HIV HIV means means freedom. freedom. ” “ I “feel I feel like like we’re we’re on on the the precipice. precipice. The The cure cure is theis the next next step. step. theironline livesvideo seriesand whataimsFreedom toFreedom a inspire cure from from the the millennialsstigma.would stigma. Freedom Freedom mean andfrom from the LGBT the virus.for virus. ” them. ” The I wantI want to beto bethere there to“ celebrateto celebrate with with everybody everybody else. else. ” ” have a new life, a new beginning for the youth. ” It was this moment of awareness. Someone’s got my back. ” communities to support HIV/AIDS research and amfAR’s FreedomFreedom from from the the stigma. stigma. Freedom Freedom from from the the virus. virus. ” ” ONGINA I wantI want to tobe be there there to tocelebrate celebrate with with everybody everybody else. else. ” ” KEN WILLIAMS online video series aims to inspire millennialsONGINAONGINA and LGBT KENKEN WILLIAMS WILLIAMSDrag performer, HIV/AIDS and trans rights advocate, Los Angeles Public speaker, AIDS activist, founder of award-winningVICTOR video LUNA blog “Ken Like Barbie,” Houston TEO DRAKE mission to find a cure. DragDrag performer, performer, HIV/AIDS HIV/AIDS and andtrans trans rights rights advocate, advocate, Los LosAngeles Angeles PublicPublic speaker, speaker, AIDS AIDS activist, activist, founder founder of award-winning of award-winning video video blog blog “Ken “Ken Like Like Barbie,” Barbie,” ONGINAHoustonONGINA Houston FashionKENKEN designer, WILLIAMS WILLIAMS Los Angeles Educator, spiritual activist, Greenfield, MA communities to support HIV/AIDS research and amfAR’s DragDrag performer, performer, HIV/AIDS HIV/AIDS and and trans trans rights rights advocate, advocate, Los Los Angeles Angeles PublicPublic speaker, speaker, AIDS AIDS activist, activist, founder founder of award-winningof award-winning video video blog blog “Ken “Ken Like Like Barbie,” Barbie,” Houston Houston mission to find a cure.

“ It’s time to end this. It’s time to bring a cure, to “ I was almost caught o guard. Someone’s still working on a cure! have a new life, a new beginning for the youth. ” It was this moment of awareness. Someone’s got my back. ”

VICTOR LUNA TEO DRAKE “ Finding a cure for HIV means freedom. “ I feel like we’re on the precipice. The cure is the next step. Fashion designer, Los Angeles Educator, spiritual activist, Greenfield, MA Freedom from the stigma.“ It’sFreedom“ It’stime time to from endto endthe this. virus. this. It’s It’s”time time to bringto bring a cure, a cure, to to I want to be“ thereI was“ I was toalmost celebrate almost caught caught with o everybody o guard. guard. Someone’s else. Someone’s ” still still working working on ona cure! a cure! “ I’m ready for a cure. “ It’s“ It’s time time to toend end this. this. It’s It’s time time to tobring bring a cure, a cure, to to “ I “was I was almost almost caught caught o o guard. guard. Someone’s Someone’s still still working working on on a cure! a cure! havehave a new a new life, life, a new a new beginning beginning for forthe the youth. youth. ” ” It wasIt was this this moment moment of awareness.of awareness. Someone’s Someone’s got got my myback. back. ” ” I’m ready to stop taking pills. ” ONGINA havehaveKEN a new aWILLIAMS new life, life, a new a new beginning beginning for for the the youth. youth. ” ” It wasIt was this this moment moment of ofawareness. awareness. Someone’s Someone’s got got my my back. back. ” ” THE EPIC VOICES VIDEOS Drag performer, HIV/AIDS and trans rights advocate, Los Angeles VICTORVICTOR LUNA LUNAPublic speaker, AIDS activist, founder of award-winning video blog “Ken Like Barbie,” Houston TEOTEO DRAKE DRAKE HYDEIA BROADBENT FashionFashion designer, designer, Los LosAngeles Angeles Educator,Educator, spiritual spiritual activist, activist,VICTOR Greenfield,VICTOR Greenfield, LUNA MA LUNA MA Educator and HIV activist, Las Vegas TEOTEO DRAKE DRAKE ARE AVAILABLE AT Educator, spiritual activist, Greenfield, MA FashionFashion designer, designer, Los Los Angeles Angeles Educator, spiritual activist, Greenfield, MA www.curecountdown.org/epicvoices “ Finding a cure for HIV means freedom. “ I feel like we’re on the precipice. The cure is the next step. Freedom from the stigma. Freedom from the virus. ” I want to be there to celebrate with everybody else. ”

ONGINA KEN WILLIAMS Drag performer, HIV/AIDS and trans rights advocate, Los Angeles Public speaker, AIDS activist, founder of award-winning video blog “Ken Like Barbie,” Houston “ I’m ready for a cure. I’m ready to stop taking pills. ” THE EPIC VOICES VIDEOS HYDEIA BROADBENT Educator and HIV activist, Las Vegas ARE AVAILABLE AT www.curecountdown.org/epicvoices “ It’s time to end this. It’s time to bring a cure, to “ I was almost caught o guard. Someone’s still working on a cure! 6 have a new life, a new beginning for the youth. ” It was this moment of awareness. Someone’s got my back. ”

“ I’m“ I’mready ready for fora cure. a cure. TEO DRAKE VICTOR LUNA “ I’m“ I’m ready ready for for a cure. a cure. I’m I’mready ready to stopto stop taking taking pills. pills. ” ” Fashion designer, Los Angeles Educator, spiritual activist, Greenfield, MA I’m ready to stopTHE takingTHE EPIC pills. EPIC ” VOICES VOICES VIDEOS VIDEOS I’m ready to stop taking pills. ” THETHE EPIC EPIC VOICES VOICES VIDEOS VIDEOS HYDEIAHYDEIA BROADBENT BROADBENT AREARE AVAILABLE AVAILABLE AT AT EducatorEducator and andHIV HIVactivist, activist, Las LasVegas Vegas HYDEIAHYDEIA BROADBENT BROADBENT AREARE AVAILABLE AVAILABLE AT AT EducatorEducator and www.curecountdown.org/epicvoicesand HIVwww.curecountdown.org/epicvoices HIV activist, activist, Las Las Vegas Vegas www.curecountdown.org/epicvoiceswww.curecountdown.org/epicvoices

“ It’s time to end this. It’s time to bring a cure, to “ I was almost caught o guard. Someone’s still working on a cure! have a new life, a new beginning for the youth. ” It was this moment of awareness. Someone’s got my back. ”

VICTOR LUNA TEO DRAKE Fashion designer, Los Angeles Educator, spiritual activist, Greenfield, MA “ I’m ready for a cure. I’m ready to stop taking pills. ” THE EPIC VOICES VIDEOS HYDEIA BROADBENT Educator and HIV activist, Las Vegas ARE AVAILABLE AT www.curecountdown.org/epicvoices

“ I’m ready for a cure. I’m ready to stop taking pills. ” THE EPIC VOICES VIDEOS HYDEIA BROADBENT Educator and HIV activist, Las Vegas ARE AVAILABLE AT www.curecountdown.org/epicvoices 2017 RESEARCH GRANTS, INVESTMENT GRANTS: BRINGING Permanent silencing of HIV-1 expression through BIOENGINEERS TO CURE HIV – PHASE I the polycomb repressor complex 2 epigenetic FELLOWSHIPS AND AWARDS pathway Single-cell transcriptomic analysis of HIV Fabio Romerio, PhD All projects listed below were awarded reservoirs before and after systemic interleukin-2 University of Maryland at Baltimore Baltimore, MD funding during the period October 1, 2016, (IL-2) therapy Eli Boritz, MD, PhD $199,999 through September 30, 2017. Foundation for the National Institutes of Health Anti-proliferative therapy for eradication of the HIV Bethesda, MD reservoir $200,000 Joshua Schiffer, MD, MSc amfAR RESEARCH CONSORTIUM ON HIV Single cell levitation to Identify, isolate and Fred Hutchinson Cancer Research Center Seattle, WA ERADICATION (ARCHE) characterize HIV reservoirs Timothy Henrich, MD $200,000 Allogeneic stem cell transplant in HIV-1-Infected University of California, San Francisco Individuals (second renewal) San Francisco, CA Annemarie Wensing, MD, PhD $200,000 MATHILDE KRIM FELLOWSHIPS IN University Medical Center Utrecht BASIC BIOMEDICAL RESEARCH Utrecht, The Netherlands Targeted nanocarriers to accelerate depletion of

Javier Martinez-Picado, PhD the HIV reservoir Impact of pre-adaptation on viral evolution and AIDS Research Institute, irsiCaixa Keith Jerome, MD, PhD virus control in the newly infected individual Barcelona, Spain University of Washington Daniela Monaco, PhD $997,518 Seattle, WA $200,000 Emory University Atlanta, GA Targeted inactivation of integrated HIV through $150,000 ARCHE: GENE THERAPY TO CURE HIV host cell DNA repair pathways Priti Kumar, PhD Exploiting dynamic conformational states of HIV-1 Yale University Env as targets for novel inhibitors Vector-mediated in vivo targeting of HIV reservoir New Haven, CT Gabriel Ozorowski, PhD cells for provirus elimination $200,000 The Scripps Research Institute Hildegard Büning, Dr. rer. nat. (PhD) La Jolla, CA Hannover Medical School Bifunctional nucleases programmed by HIV-1 $150,000 Hannover, Germany mRNA for reservoir eradication $386,578 Jeremy Luban, MD Harnessing NK cell responses to eliminate HIV-1- University of Massachusetts Medical School infected cells Subcutaneous administration of DARPin-modified Worcester, MA Jonathan Richard, PhD adeno-associated virus vectors for selective $200,000 Université de Montréal, Centre de Recherche du targeting of CD4+ T cells CHUM Keith Jerome, MD, PhD Deciphering latency-associated sugar-code to Montreal, Canada University of Washington detect and eliminate latent reservoir $150,000 Seattle, WA Hui Zhang, PhD $399,955 Johns Hopkins University Baltimore, MD Engineering blood cells to produce broadly $199,444 PHASE II MATHILDE KRIM FELLOWSHIP neutralizing anti-HIV antibodies GRANT Hans-Peter Kiem, MD, FACP Structural analyses of antibody-virus complexes Fred Hutchinson Cancer Research Center INNOVATION GRANTS: EXPLORING THE to guide immunogen design Seattle, WA USA POTENTIAL FOR HIV ERADICATION Daniela Fera, PhD $200,000 Swarthmore College Ixazomib to reduce HIV reservoir size Swarthmore, PA Optimized efficacy and persistence of engineered Andrew Badley, MD $80,000 HIV-specific cellular immunity Mayo Clinic College of Medicine Scott Kitchen, PhD Rochester, MN University of California, Los Angeles $200,000 Los Angeles, CA MEETINGS AND CONFERENCES $400,000 Creation of CCR5 knockout Mauritian cynomolgus macaques for stem cell transplants Advanced Course on HIV Pathogenesis, XII LentiStim: mass production of lentiviral vectors for Benjamin Burwitz, PhD Edition in vivo gene delivery Oregon Health and Science University Esper Kallás, MD, PhD Yasuhiro Takeuchi, PhD Portland, OR Fundação Faculdade de Medicina University College London $199,948 São Paulo, Brazil $15,000 London, United Kingdom Disabling HIV provirus by promoting $360,034 chromatinization Andrew Henderson, PhD Targeting of nucleic acid therapeutics to cure HIV Boston University School of Medicine Drew Weissman, MD, PhD Boston, MA Trustees of the University of Pennsylvania $200,000 Philadelphia, PA $400,000 HLA-E-specific TCR-like antibodies for the universal targeting of persistent HIV reservoirs CAR T cells dually encoding alpha-chain- Brad Jones, PhD anchored and soluble broadly neutralizaing The George Washington University antibodies to HIV Washington, DC Richard T. Wyatt, PhD $199,998 International AIDS Vaccine Initiative New York, NY $199,362

7 2017 TREAT ASIA GRANTS RPA Sexual Health Clinic Royal Perth Hospital Camperdown Perth AND AWARDS David Templeton, PhD David Nolan, MBBS, FRACP, PhD $5,550 $6,8251 All projects listed below were awarded Melbourne Sexual Health Centre Prahran Market Clinic Pty Ltd funding during the period October 1, 2016, Carlton Prahran through September 30, 2017. Tim Read, MBBS, DipVen, FRACGP, FAChSHM, Norman Roth, MBBS, FAChSHM EpiDip $6,8251 $6,2251 1Supported by National Institutes of Health Holdsworth House Medical Practice cooperative agreement number U01AI069907 with Monash Health - Clayton Sydney Clayton Mark Bloch, MD funds from the National Institute of Allergy and Ian Woolley, MBBS, FRACP $7,5001 Infectious Diseases, the Eunice Kennedy Shriver $7,5001 National Institute of Child Health and Human Sydney Sexual Health Centre, Sydney Hospital D.A. Ellis Pty Ltd Sydney Development, the National Cancer Institute, Coffs Harbour Rick Varma, MBBS, MRCP the National Institute of Mental Health, and the David Ellis, MBBS $6,6001 National Institute on Drug Abuse $675 Clinic 468, HNE Sexual Health, Hunter New 2Supported by National Institutes of Health grant East Sydney Doctors England Local Health District Darlinghurst Tamworth number R01HD073972 funded by the Eunice David Baker, MB, ChB, Dip Med (Sexual Health), Nathan Ryder, MD Kennedy Shriver National Institute of Child Health DCH $1,575 and Human Development $6,6751 Illawarra Shoalhaven Local Health District 3Supported by National Institutes of Health grant St. Vincent’s Hospital Sydney Limited ABN 77 054 Warrawong number R21HD089859 funded by the Eunice 038 872 Katherine Brown, MD Darlinghurst $1,800 Kennedy Shriver National Institute of Child Health David A. Cooper, MD and Human Development $7,5001 4Supported with funds provided by Taylor Square Private Clinic CAMBODIA ViiV Healthcare Darlinghurst Robert Finlayson, MBBS (Syd), Di National Center for HIV/AIDS, Dermatology 1 & STDS / Cambodia National Institute of 5Supported with funds provided by LIFE+ $6,975 Public Health 6Supported with fund provided by the Open Northern Territory Dept of Health & Community Phnom Penh Services, Sexual Health & Blood Borne Virus Ly Penh Sun, MD, MSc Society Foundations Program TAHOD Low Intensity Transfer (TAHOD LITE) Darwin $8,0001 Manoji Gunathilake, MBBS, MD, FAChSHM $1,800 TREAT Asia HIV Observational Database (TAHOD) AUSTRALIA $20,0001 Gladstone Road Medical Centre University of New South Wales Highgate Hill TREAT Asia Pediatric HIV Observational Sydney David Orth, MBBS, DIP Ven Database (TApHOD) Matthew G. Law, PhD $6,5251 $25,000 IeDEA Asia-Pacific Research Collaboration: Cancer Studies Nepean Blue Mountains Local Health District, 1 $77,277 Blue Mountains Sexual Health and HIV Clinic CHINA Katoomba IeDEA Asia-Pacific Research Collaboration: Eva Jackson, MBBS, FAChSHM Beijing Ditan Hospital TREAT Asia HIV Observational Database & $2,025 Beijing Australia HIV Observational Database Fujie Zhang, MD, MSPH, PhD 1 $299,701 Nepean Blue Mountains Local Health District, TREAT Asia HIV Observational Database (TAHOD) Nepean Sexual Health Clinic $18,5001 IeDEA Asia-Pacific Research Collaboration: Kingswood TREAT Asia Pediatric HIV Observational Database Eva Jackson, MBBS, FAChSHM Queen Elizabeth Hospital 1 $207,583 $2,100 Hong Kong Man Po Lee, MBBS Sexual Health and AIDS Services (SHAIDS) TAHOD Low Intensity Transfer (TAHOD LITE) AUSTRALIA HIV OBSERVATIONAL DATABASE Lismore $6,5001 (AHOD) SITES David Smith, MBBS, DipVen, FAChSHM, GrapDip, BA Man Po Lee, MBBS 1 O’Brien Street Practice $7,500 TREAT Asia HIV Observational Database (TAHOD) Adelaide including NCD Data Victorian HIV Service, Infectious Diseases $23,0001 William Donohue, MBBS Department, The Alfred Hospital $1,800 Melbourne Sexual Health and HIV Service In Metro North Jennifer Hoy, MBBS 1 INDIA Brisbane $7,500 Diane Rowling, MBBS, FAFPHM, RACP, FAChSHM Sunshine Coast Hospital and Health Service Chennai Antiviral Research and Treatment Clinical $3,825 Nambour West Research Site (CART CRS), YRG CARE Medical Centre, VHS Cairns Sexual Health Service David Sowden, MBBS $7,5001 Chennai Cairns Naglingeswaran Kumarasamy, MD, MBBS, PhD Darren Russell, MD Northside Clinic (Vic) Pty Ltd TAHOD Low Intensity Transfer (TAHOD LITE) 1 $7,500 North Fitzroy $5,000 Richard Moore, MBBS $7,5001

8 TREAT Asia HIV Observational Database (TAHOD) MALAYSIA SOUTH KOREA including NCD Data $21,8001 Penang Hospital Yonsei University College of Medicine Georgetown Seoul TREAT Asia Pediatric HIV Observational Database Revathy Nallusamy, MBBS Jun Yong Choi, MD, PhD (TApHOD) Site TREAT Asia Pediatric HIV Observational Database TAHOD Low Intensity Transfer (TAHOD LITE) $7,500 (TApHOD) $5,0001 $2,500 B.J. Medical College TREAT Asia HIV Observational Database (TAHOD) Pune Hospital Raja Perempuan Zainab II including NCD Data Aarti Kinikar, MD, DCH, DNB, MRCP Kota Bharu $18,2001 TREAT Asia Pediatric HIV Observational Database Nik Khairulddin Nik Yusoff, MD (TApHOD) Site TREAT Asia Pediatric HIV Observational Database 1 $20,000 (TApHOD) TAIWAN $7,500 Shahshikala Sangle Taipei Veterans General Hospital TREAT Asia HIV Observational Database (TAHOD) Hospital Likas Taipei City including NCD Data Kota Kinabalu 1 Wing-Wai Wong, MD $22,550 Fong Siew Moy, MBBS TAHOD Low Intensity Transfer (TAHOD LITE) TREAT Asia Pediatric HIV Observational Database $5,0001 B.J. Medical College—Johns Hopkins University (TApHOD) Pune $7,500 TREAT Asia HIV Observational Database (TAHOD) Vidya Mave, MD, MPH including NCD Data Epidemiology of HIV/AIDS and associated Pediatric Institute, Hospital Kuala Lumpur $26,0001 comorbidities in a public antiretroviral treatment Kuala Lumpur (ART) clinic in Pune, India Thahira Mohamed, MBBS $212,5511 TREAT Asia Pediatric HIV Observational Database (TApHOD) THAILAND Institute of Infectious Diseases $7,500 Pune Chulalongkorn University Sanjay Pujari, MD, AAHIVS, MBBS University of Malaya Bangkok TAHOD Low Intensity Transfer (TAHOD LITE) Kuala Lumpur Thanyawee Puthanakit, MD $7,992 Adeeba Kamarulzaman, MBBS, FRACP, FAMM, Neurodevelopmental and neurobehavioral TREAT Asia HIV Observational Database (TAHOD) FASc outcomes in HIV-exposed children 1 1 including NCD Data TREAT Asia HIV Observational Database (TAHOD) $10,174 (Year 1) $13,883 (Year 2) 1 $22,400 including NCD Data TREAT Asia Pediatric HIV Observational Database 1 $22,700 (TApHOD) 1 Sungai Buloh Hospital $15,000 INDONESIA Sungai Buloh HIV-NAT / Thai Red Cross AIDS Research Centre Sanglah Hospital, Udayana University School of Yasmin Mohamed Gani, MD Bangkok Medicine Study of Transitioning Asian Youth (STAY) Anchalee Avihingsanon, MD, PhD 4 Denpasar, Bali $6,986 TREAT Asia HIV Observational Database (TAHOD) Tuti Parwati Merati, MD, PhD Benedict Lim Heng Sim, MBBS, MRCP including NCD Data 1 TAHOD Low Intensity Transfer (TAHOD LITE) TREAT Asia HIV Observational Database (TAHOD) $23,200 $6,5001 including NCD Data Sivaporn Gatechompol 1 TREAT Asia HIV Observational Database (TAHOD) $16,000 Human Papillomavirus Infection in Perinatally HIV- including NCD Data infected Adolescents in Asia $22,5501 $15,0822 NEPAL Ketut Dewi Kumara Wati, MD Watsamon Jantarabenjakul, MD TREAT Asia Pediatric HIV Observational Database Union C Treatment switch from efavirenz to rilpivirine (TApHOD) Kathmandu in virologically-suppressed HIV-infected Thai $7,500 Himal Gauchan adolescents Hepatitis C capacity development for community $2,355 Cipto Mangunkusumo General Hospital groups Jakarta $8,3996 Stephen Kerr, PhD Nia Kurniati, MD Study of Transitioning Asian Youth (STAY) Statistical TREAT Asia Pediatric HIV Observational Database Analysis Center (TApHOD) $10,0461 $7,5001 SINGAPORE Understanding adherence, stigma, and behavioral Evy Yunihastuti, MD, PhD Tan Tock Seng Hospital risk factors of adolescents in TApHOD using ACASI TREAT Asia HIV Observational Database (TAHOD) Singapore (data analysis center) including NCD Data Oon Tek Ng, MBBS, MRCP, MMed, MPH $4,0001 $22,8001 TAHOD Low Intensity Transfer (TAHOD LITE) $5,0001 Nittaya Phanuphak, MD, PhD Human Papillomavirus Infection in Perinatally HIV- TREAT Asia HIV Observational Database (TAHOD) infected Adolescents in Asia (central lab & data 1 JAPAN $18,000 management) National Center for Global Health and Medicine $110,9622 Shinjuku SOUTH AFRICA Amphetamine-type stimulant use, HIV incidence, Junko Tanuma, MD, PhD and ART adherence among Thai MSM and TREAT Asia HIV Observational Database (TAHOD) 1 University of Cape Town transgender women $16,000 Mowbray $32,6701 (Year 1) $75,6011 (Year 2) Mary-Ann Davies, MBChB, MMed., FCPHM Global fRAmework for Data Collection Used for Anal HPV and risk for anal high-grade squamous Adolescent HIV Transition Evaluation (GRADUATE) intraepithelial lesion among Thai MSM with acute $102,1053 (Year 1) $91,4773 (Year 2) HIV infection $30,1791 (Year 1) $77,3591 (Year 2)

9 Mahidol University by Faculty of Medicine Siriraj Purple Haze Company Limited 2017 GMT INITIATIVE Hospital Muang Bangkok Tarandeep Anand GRANTS AND AWARDS Kulkanya Chokephaibulkit, MD The impact of online interventions on the HIV Human Papillomavirus Infection in Perinatally HIV- prevention/treatment cascade among MSM and All projects listed below were awarded infected Adolescents in Asia TG Individuals $11,6582 $30,0281 (Year 2) $30,0001 (Year 3) amfAR funding during the period October 1, 2016, through September 30, 2017. Study of Transitioning Asian Youth (STAY) $12,4541 USA amfAR HIV SCHOLARS AWARDS TREAT Asia Pediatric HIV Observational Database (TApHOD) Massachusetts General Hospital $15,0001 Boston, MA Structural intervention models for HIV prevention Andrea Ciaranello, MD, MPH among young gay men and transgender Treatment switch from efavirenz to rilpivirine Estimating the magnitude of the pediatric and individuals in central São Paulo in virologically-suppressed HIV-infected Thai adolescent HIV epidemic in Thailand Daniel Barros adolescents $45,0005 Santa Casa School of Medical Sciences $7,961 São Paulo, Brazil $25,000 Queen Sirikit National Institute of Child Health VIETNAM Bangkok Pilot study on HIV among men who have sex with Piyarat Suntarattiwong, MD Bach Mai Hospital men in Belize (supplement) Treatment switch from efavirenz to rilpivirine Hanoi Erika Castellanos in virologically-suppressed HIV-infected Thai Do Duy Cuong, MD, PhD Collaborative Network of Persons Living with HIV adolescents TAHOD Low Intensity Transfer (TAHOD LITE) (C-NET+) $6,260 $6,5001 Belize City, Belize $1,800 Ramathibodi Hospital, Mahidol University TREAT Asia HIV Observational Database (TAHOD) Bangkok including NCD Data Project Power-Up – Developing a peer support Sasisopin Kiertiburanakul, MD, MHS $22,6701 TREAT Asia HIV Observational Database (TAHOD) group for HIV-positive GMT in Mpumalanga, including NCD Data Nguyen Van Lam, MD, MSc South Africa $23,0001 Study of Transitioning Asian Youth (STAY) Kabelo Maleke $8,8034 Anova Health Institute Chiang Mai University - Research Institute for Cape Town, South Africa Health Sciences TREAT Asia Pediatric HIV Observational Database $25,000; Supplement: $862 Chiang Mai (TApHOD) Romanee Chaiwarith, MD, MHS $20,0001 Developing ‘GAP,’ a smartphone application for TREAT Asia HIV Observational Database (TAHOD) daily self-monitoring and self-management for including NCD Data Nguyen Van Kinh, MD, PhD HIV-positive MSM $23,9001 TAHOD Low Intensity Transfer (TAHOD LITE) Adi Nugroho 1 $6,500 GWL-INA Tavitiya Sudjaritruk, MD, ScM TREAT Asia HIV Observational Database (TAHOD) Jakarta, Indonesia TREAT Asia Pediatric HIV Observational Database $25,000 (TApHOD) including NCD Data 1 1 $22,560 $15,000 HIV care access and retention in Paraguay: Chiangrai Prachanukroh Hospital Children’s Hospital 1 A comparative analysis of the country’s first Chiang Rai Ho Chi Minh City LGBT clinic Rawiwan Hansudewechakul, MD Tran Ngoc Hanh Dan, MD, MSc Antonio Spagnolo, MD Human Papillomavirus Infection in Perinatally Human Papillomavirus Infection in Perinatally Fundación Vencer HIV-infected Adolescents in Asia HIV-infected Adolescents in Asia Asunción, Paraguay 2 $11,1022 $4,802 $23,000 Study of Transitioning Asian Youth (STAY) Truong Huu Khanh, MD $10,1724 TREAT Asia Pediatric HIV Observational Database (TApHOD) TREAT Asia Pediatric HIV Observational Database $25,0001 (TApHOD) $15,0001 Do Chau Viet, MD TREAT Asia Pediatric HIV Observational Database Suwimon Khusuwan (TApHOD) TREAT Asia HIV Observational Database (TAHOD) $20,000 including NCD Data $22,5001 Hung Vuong Hospital Ho Chi Minh City Srinagarind Hospital, Khon Kaen University Dang Le Dung Hanh, MD (OB&GYN), MA Khon Kaen Human Papillomavirus Infection in Perinatally Pagakrong Lumbiganon, MD HIV-infected Adolescents in Asia Study of Transitioning Asian Youth (STAY) $4,6492 $11,5994 TREAT Asia Pediatric HIV Observational Database (TApHOD) $7,500

10 2017 PUBLIC POLICY 2017 COMMUNITY AWARDS OUTREACH AWARDS

The projects listed below were awarded The projects listed below were awarded amfAR funding during the period October 1, amfAR funding during the period October 1, 2016, through September 30, 2017. 2016, through September 30, 2017.

*Funded with support from the Ford Foundation

Building power in prevention advocacy among Dr. Mathilde Krim/amfAR Professorship of Global transgender African advocates Health Fund Emily Bass Columbia University AIDS Vaccine Advocacy Coalition (AVAC) New York, NY New York, NY $500,000 $49,999 Andrea Bocelli Foundation—Health Care Needs Scrutinizing PEPFAR Investments in South Africa of People Living with HIV in Haiti Matthew Kavanagh, PhD Charities Aid Foundation of America Georgetown University (CAF America) Washington, DC Alexandria, VA $47,928 $224,260 Qualitative evaluation of retention at the Moore Charlize Theron Africa Outreach Project Clinic New Venture Fund Catherine Maulsby, PhD Washington, DC Johns Hopkins University $500,000 Baltimore, MD $99,942*

11 12 Financial Highlights For the year ended September 30, 2017

Public Support and Revenue Public support $ 6,281,507 Special events 18,185,017 Planned giving 3,157,413 Government funding 11,578,195 Investment income and other revenue 2,355,134 Total public support and revenue $ 41,557,266

Expenses Research $ 22,716,644 TREAT Asia 4,581,509 GMT Initiative 1,272,304 Public Policy 2,202,676 Public Information 4,230,300 Total program services $ 35,003,433

Fundraising 5,779,044 Management and general 2,683,723 Total supporting services $ 8,462,767

Total expenses $ 43,466,200

Change in net assets (1,908,934) Net assets, beginning of year 61,639,180

Net assets, end of year $ 59,730,246

Statement of Financial Position

Assets Cash and investments $ 63,694,070 Pledges and receivables, net 8,619,990 Prepaid expenses and other assets 4,833,160 Furniture, equipment, and leasehold improvements, net 3,074,500 Total Assets $ 80,221,720

Liabilities Accounts payable and accrued expenses $ 3,028,826 Grants and fellowships payable, net 3,445,162 Deferred support and refundable advances 11,985,013 Other long-term liabilities 2,032,473 Total liabilities $ 20,491,474

Total net assets 59,730,246

Total liabilities and net assets $ 80,221,720

13 Expenses

Fundraising $ 5,779,044 Management and general 2,683,723 Program 35,003,433

Total $ 43,466,200

Program Expenses

Research $ 22,716,644 TREAT Asia 4,581,509 GMT Initiative 1,272,304 Public Policy 2,202,676 Public Information 4,230,300

Total $ 35,003,433

14 Jay Ellis TRUSTEE EMERITUS BOARD OF TRUSTEES Jay Ellis Foundation Fiscal year 2017 Studio City, CA Arthur J. Ammann, M.D. President, Global Strategies for HIV Prevention Aileen Getty Chairman of the Board Clinical Professor of Pediatrics The Aileen Getty Foundation Kenneth Cole University of California, San Francisco Del Mar, CA Chairman San Francisco, CA Kenneth Cole Productions T. Ryan Greenawalt New York, NY Managing Director Ramirez & Co. Founding Chairman IN MEMORIAM President Mathilde Krim, Ph.D. Harrison Street Productions Adjunct Professor Dame Elizabeth Taylor New York, NY Mailman School of Public Health Founding International Chairman Columbia University Regan Hofmann Sheldon W. Andelson, Esq. New York, NY Policy Officer Arnold W. Klein, M.D. U.S. Liaison Office Vice Chairman Mrs. Albert D. Lasker UNAIDS Patricia J. Matson Jonathan M. Mann, M.D., M.P.H. Washington, D.C. Senior Vice President, Communications (ret.) Maxine Mesinger ABC, Inc. Michael J. Klingensmith Pauline Phillips New York, NY Publisher and CEO Natasha Richardson Star Tribune Allan Rosenfield, M.D. Vice Chairman and Treasurer Minneapolis, MN Peter Scott, Esq. John C. Simons Tom Stoddard Managing Partner Kevin McClatchy Joel D. Weisman, D.O. Corporate Fuel Partners, LLC Chairman of the Board New York, NY The McClatchy Company Ligonier, PA Secretary SPECIAL APPOINTMENTS Mervyn F. Silverman, M.D., M.P.H. Michele V. McNeill, Pharm.D. President Chairman Global Campaign Chair Mervyn F. Silverman Associates McNeill Family Foundation Sharon Stone Crockett, CA Sarasota, FL Global Fundraising Chairman Edward L. Milstein Milutin Gatsby Co-Chairman, Milford Management TRUSTEES Co-Chairman, Emigrant Savings Bank Partner, Milstein Properties amfAR AMBASSADORS Arlen H. Andelson New York, NY Senior Partner (ret.) Peter Piot, M.D., Ph.D. Cheyenne Jackson Andelson & Andelson Janet Jackson Los Angeles, CA Director London School of Hygiene & Tropical Medicine Milla Jovovich Harry Belafonte London, UK Liza Minnelli President Michelle Yeoh Belafonte Enterprises, Inc. Cindy D. Rachofsky New York, NY Philanthropist Dallas, TX David Bohnett COMMITTEES OF THE BOARD Chairman Vincent A. Roberti OF TRUSTEES David Bohnett Foundation Chairman, Roberti Global, LLC Beverly Hills, CA Managing Director, Roberti Associates Global, LLC Executive Washington, D.C. Zev Braun Kenneth Cole, Chair President and CEO Bill Roedy Michael J. Klingensmith Braun Entertainment Group, Inc. London, UK Mathilde Krim, Ph.D. Beverly Hills, CA Patricia J. Matson Raymond F. Schinazi, Ph.D., D.Sc. Vincent A. Roberti Jonathan S. Canno Frances Winship Walters Professor of Pediatrics Mervyn F. Silverman, M.D., M.P.H. New York, NY Director, Laboratory of Biochemical Pharmacology John C. Simons Emory University Donald A. Capoccia Decatur, GA Audit Managing Principal John Simons, Chair BFC Partners Alan D. Schwartz R. Martin Chavez, Ph.D. Brooklyn, NY Executive Chairman T. Ryan Greenawalt Guggenheim Partners, LLC R. Martin Chavez, Ph.D. New York, NY Board Development Chief Information Officer Donald A. Capoccia, Co-Chair The Goldman Sachs Group, Inc. Diana L. Taylor Patricia J. Matson, Co-Chair New York, NY Vice Chair Arlen Andelson Solera Capital, LLC T. Ryan Greenawalt Jane B. Eisner New York, NY Bill Roedy President Mervyn F. Silverman, M.D., M.P.H. The Eisner Foundation Bel Air, CA Communications/Social Media/Marketing Regan Hofmann, Chair Kenneth Cole T. Ryan Greenawalt Patricia J. Matson Kevin McClatchy Vincent A. Roberti Bill Roedy

15 Compensation and Organizational Development Tony Boitano, Ph.D.* Grant Colfax, M.D. John C. Simons, Chair Vice President of Stem Cell Biology Director Michael J. Klingensmith Magenta Therapeutics Marin Health and Human Services Kevin McClatchy San Rafael, California Eli Boritz, M.D., Ph.D.* Finance & Budget Chief, Virus Persistence and Dynamics Section Jessica Conway, Ph.D.* Michael J. Klingensmith, Chair Vaccine Research Center Assistant Professor of Mathematics Vincent A. Roberti National Institute of Allergy and Infectious The Huck Institutes of the Life Sciences John C. Simons Diseases The Pennsylvania State University National Institutes of Health Fund Development Deborah Jean Cotton, M.D., M.P.H. Vincent A. Roberti, Chair Alberto Bosque, Ph.D.* Professor of Medicine Arlen Andelson Assistant Professor Boston University School of Medicine Jonathan S. Canno Department of Microbiology, Immunology, and Donald A. Capoccia Tropical Medicine Bryan R. Cullen, Ph.D., D.Sc. T. Ryan Greenawalt The George Washington University James B. Duke Professor Cindy D. Rachofsky Department of Molecular Genetics and Raymond F. Schinazi, Ph.D., D.Sc. Jason Brenchley, Ph.D.* Microbiology Investment Senior Investigator Director, Duke University Center for Virology Michael J. Klingensmith, Chair Immunopathogenesis Section Duke University Medical Center R. Martin Chavez, Ph.D. National Institute of Allergy and Infectious Susanna Cunningham-Rundles, Ph.D. T. Ryan Greenawalt Diseases Professor Emerita of Research Immunology Edward L. Milstein National Institutes of Health Department of Pediatrics Vincent A. Roberti Dennis R. Burton, Ph.D. Weill Cornell Medical College John C. Simons Professor Department of Immunology Satya Dandekar, Ph.D.* The Scripps Research Institute Professor and Chair Department of Medical Microbiology and Shilpa Buch, Ph.D.* Immunology Professor University of California, Davis SCIENTIFIC ADVISORY Department of Pharmacology and Experimental COMMITTEE Neuroscience Richard Thomas D’Aquila, M.D. University of Nebraska Medical Center The Howard Taylor Ricketts Professor of Medicine Division of Infectious Diseases Christian Buchholz, Ph.D.* Director, Northwestern HIV Translational *Adjunct Member Head of Section Research Center Molecular Biotechnology and Gene Therapy Feinberg School of Medicine Daniel C. Douek, M.D., Ph.D. (Chair) Paul-Ehrlich-Institut Northwestern University Chief, Human Immunology Section Vaccine Research Center Salvatore T. Butera, D.V.M., Ph.D. Steven Deeks, M.D.* National Institute of Allergy and Infectious Chief Science Officer Professor Diseases Scripps CHAVI-ID Department of Medicine National Institutes of Health The Scripps Research Institute University of California, San Francisco

Margaret Ackerman, Ph.D.* Edward Campbell, Ph.D. Bruno De Geest, Ph.D. Associate Professor of Engineering Assistant Professor Chemical Engineer Thayer School of Engineering Department of Microbiology and Immunology Laboratory of Pharmaceutical Technology Dartmouth College School of Medicine Ghent University Hospital Loyola University at Chicago Richard Ambinder, M.D., Ph.D.* Sherry Deren, Ph.D. Director, Division of Hematologic Malignancies Toni Cathomen, Ph.D.* Co-Director Professor of Oncology Professor, Center for Chronic Immunodeficiency Center for Drug Use and HIV Research School of Medicine Director, Institute for Cell and Gene Therapy New York University College of Nursing Johns Hopkins University University Medical Center Freiburg Roger Detels, M.D., M.S. Angelina Angelova, Ph.D.* Alex Carballo-Dieguez, Ph.D. Professor of Epidemiology Research Associate Co-Director and Senior Research Scientist School of Public Health Physico-Chimie des Systèmes Polyphasés HIV Center for Clinical and Behavioral Studies University of California, Los Angeles Université Paris-Sud New York State Psychiatric Institute Columbia University Carl W. Dieffenbach, Ph.D. Patrick Arbuthnot, Ph.D.* Director Director Ann Chahroudi, M.D., Ph.D.* Division of AIDS (DAIDS) Antiviral Gene Therapy Research Unit Associate Director, Clinical Affairs National Institute of Allergy and Infectious University of the Witwatersrand School of Medicine Diseases Emory University National Institutes of Health Dan Barouch, M.D., Ph.D.* Professor *Nicolas Chomont, Ph.D. David DiGiusto, Ph.D.* Ragon Institute of MGH, MIT and Havard Assistant Professor Executive Director of Stem Cell and Cellular Beth Israel Deaconess Medical Center Microbiology and Immunology Therapeutic Operations Université de Montréal, Centre de Recherche du Senior Academic Researcher in the Division of Jeffrey Bartlett, Ph.D.* CHUM Stem Cell Transplantation and Regenerative Chief Scientific Officer Medicine Senior Vice President, Research and Development David B. Clifford, M.D. Stanford University Calimmune, Inc. Professor Department of Neurology Robert W. Doms, M.D., Ph.D.* Michael Betts, Ph.D.* Washington University School of Medicine Professor of Pathology and Laboratory Medicine Associate Professor Department of Pathology and Laboratory Medicine Department of Microbiology C. Budd Colby, Ph.D. University of Pennsylvania Perelman School of Medicine Principal University of Pennsylvania Colby Biomedical Ventures 16 D. Peter Drotman, M.D., M.P.H. Daria Hazuda, Ph.D.* Stephen Kaminsky, Ph.D.* Editor-in-Chief Vice President, Infectious Diseases Discovery Associate Director, Belfer Gene Therapy Emerging Infectious Diseases and Chief Scientific Officer Core Facility Centers for Disease Control and Prevention MRL Cambridge Exploratory Science Center Professor of Research in Genetic Medicine Merck & Co., Inc. Department of Genetic Medicine Anke A. Ehrhardt, Ph.D. Weill Medical College of Cornell University Director Frederick Hecht, M.D.* Division of Gender, Sexuality, & Health Professor Jonathan Karn, Ph.D.* Program for the Study of LGBT Health Department of Medicine Director NYS Psychiatric Institute/Columbia University University of California, San Francisco Center for AIDS Research Case Western Reserve University Homayoon Farzadegan, Ph.D. Andrew Henderson, Ph.D.* Professor Associate Professor Fatah Kashanchi, Ph.D.* Department of Epidemiology School of Medicine Professor Johns Hopkins Bloomberg School of Public Health Boston University National Center for Biodefense and Infectious Disease Michael Farzan, Ph.D.* Timothy Henrich, M.D.* George Mason University Vice Chairman and Professor Assistant Professor of Medicine Department of Immunology and Microbial Science, Division of Infectious Disease Daniel Kaufmann, M.D.* Florida Campus University of California, San Francisco Associate Professor The Scripps Research Institute Department of Medicine Charles H. Hinkin, Ph.D. Université de Montréal, Centre de Recherche du Dianne M. Finkelstein, Ph.D. Professor CHUM Professor of Biostatistics Department of Psychiatry and Biobehavioral Harvard School of Public Health Sciences Brandon Keele, Ph.D.* Director of the Cancer Center Biostatics David Geffen School of Medicine Principal Investigator / Senior Principal Scientist Massachusetts General Hospital University of California, Los Angeles Frederick National Laboratory for Cancer Research National Cancer Institute Andrés Finzi, Ph.D.* Catarina Hioe, Ph.D.* Associate Professor Professor Vineet KewalRamani, Ph.D. Department of Microbiology and Immunology Medicine, Infectious Diseases, and Microbiology Chief, Model Development Section Université de Montréal, Centre de Recherche du Icahn School of Medicine at Mount Sinai HIV Drug Resistance Program CHUM National Cancer Institute David Ho, M.D. National Institutes of Health Gerald Herbert Friedland, M.D. Scientific Director, Chief Executive Officer Professor and Director Aaron Diamond AIDS Research Center Sanggu Kim, Ph.D.* AIDS Care Program Assistant Professor Department of Internal Medicine Thomas J. Hope, Ph.D. Department of Veterinary Biosciences Yale School of Medicine Professor The Ohio State University Department of Cell and Molecular Biology Rémi Fromentin, Pharm.D., Ph.D.* Feinberg School of Medicine Scott Kitchen, Ph.D. Postdoctoral Researcher Northwestern University Assistant Professor of Medicine Université de Montréal, Centre de Recherche du Division of Hematology and Oncology CHUM Bonnie Howell, Ph.D.* David Geffen School of Medicine Executive Director, Infectious Disease and University of California, Los Angeles Rajesh Gandhi, M.D.* Vaccines Director, HIV Clinical Services and Education Merck & Co., Inc. Nicole Klatt, Ph.D.* Massachusetts General Hospital Assistant Professor Shiu-Lok Hu, Ph.D. Department of Pharmaceutics Nilu Goonetilleke, Ph.D.* Professor School of Pharmacy Assistant Professor School of Pharmacy University of Miami, School of Medicine Department of Microbiology & Immunology University of Washington The University of North Carolina at Chapel Hill Richard Kornbluth, M.D., Ph.D. Judd Hultquist, Ph.D.* President and Chief Scientific Officer Howard E. Gendelman, M.D. Postdoctoral Scholar Multimeric Biotherapeutics, Inc. Professor and Chair, Department of Pharmacology Gladstone Institutes and Experimental Neuroscience Richard A. Koup, M.D. Margaret R. Larson Professor of Internal Medicine Peter Hunt, M.D.* Deputy Director, Vaccine Research Center and Infectious Diseases Associate Professor Chief, Immunology Laboratory Director, Center for Neurodegenerative Disorders Department of Medicine National Institute of Allergy and Infectious University of Nebraska Medical Center University of California, San Francisco Diseases National Institutes of Health Warner Greene, M.D., Ph.D.* Gero Hütter, M.D., Ph.D.* Professor Medical Director, Cellex Smita Kulkarni, Ph.D.* Director and Senior Investigator, Center for HIV Assistant Scientist Cure Research R. Paul Johnson, M.D.* Department of Genetics Gladstone Institutes Professor of Medicine Texas Biomedical Research Institute Director, Yerkes National Primate Research Center Nancy L. Haigwood, Ph.D. Emory University Priti Kumar, Ph.D.* Director and Senior Scientist Associate Professor Division of Pathobiology and Immunology Brad Jones, Ph.D.* Department of Infectious Diseases Oregon National Primate Research Center Assistant Professor Yale University Oregon Health and Science University Microbiology, Immunology & Tropical Medicine The George Washington University Daniel Kuritzkes, M.D.* Brendan Harley, Ph.D.* Harriet Ryan Albee Professor of Medicine Associate Professor and Robert W. Schaefer Department of Medicine Faculty Scholar Brigham and Women’s Hospital Department of Chemical & Biomolecular Engineering University of Illinois

17 Nathaniel R. Landau, Ph.D. David M. Margolis, M.D. Nancy Padian, Ph.D., M.P.H. Professor Professor of Medicine, Microbiology, Adjunct Professor of Epidemiology Department of Microbiology Immunology, and Epidemiology School of Public Health New York University School of Medicine School of Medicine University of California, Berkeley University of North Carolina at Chapel Hill Alan L. Landay, Ph.D. Savita Pahwa, M.D. Professor and Chairman Martin H. Markowitz, M.D. Professor of Microbiology and Immunology Department of Immunology and Microbiology Professor and Clinical Director Professor in Pediatrics and Medicine Rush-Presbyterian-St. Luke’s Medical Center Aaron Diamond AIDS Research Center Director of the Miami Center for AIDS Research University of Miami Leonard M. Miller School of Michael Lederman, M.D. Javier Martinez-Picado, Ph.D.* Medicine Scott R. Inkley Professor of Medicine ICREA Research Professor Associate Director, Center for AIDS Research Life and Medical Sciences Tristram G. Parslow, M.D., Ph.D. Case Western Reserve University AIDS Research Institute irsiCaixa and UVic-UCC William Patterson Timmie Professor and Chair Department of Pathology and Laboratory Medicine Tun-Hou Lee, D.Sc. Fulvio Mavilio, Ph.D.* Emory University School of Medicine Professor of Virology, Emeritus Scientific Director Department of Immunology and Infectious Genethon Matija Peterlin, M.D. Diseases Professor of Medicine, Microbiology and Harvard School of Public Health Kenneth Hugh Mayer, M.D. Immunology Infectious Disease Attending & Director of HIV Department of Medicine Michael J. Leibowitz, M.D., Ph.D. Prevention Research University of California, San Francisco Professor, Medical Microbiology and Immunology Beth Israel Deaconess Medical Center University of California, Davis Professor of Medicine Sudheesh Pilakka Kanthikeel, Ph.D.* Harvard Medical School Assistant Professor Kam W. Leong, Ph.D.* Medical Research Director, Co-Chair Department of Immunology Samuel Y. Sheng Professor of Biomedical The Fenway Institute/Fenway Health Florida International University Engineering Department of Biomedical Engineering Joseph M. McCune, M.D., Ph.D. Vicente Planelles, Ph.D.* Columbia University Professor of Medicine Professor Department of Medicine Department of Pathology Robert J. Levine, M.D. University of California, San Francisco University of Utah Professor of Medicine Center for Interdisciplinary Research on AIDS Adrian McDermott, M.Sc., Ph.D.* Vinayaka Prasad, Ph.D.* Yale University Chief, Vaccine Immunology Program Professor Vaccine Research Center Department of Microbiology and Immunology Sharon Lewin, F.R.A.C.P., Ph.D.* National Institute of Allergy and Infectious Albert Einstein College of Medicine Director Diseases Peter Doherty Institute for Infection and Immunity National Institutes of Health Lynn Pulliam, Ph.D. University of Melbourne Professor David McDonald, Ph.D.* Department of Laboratory Medicine and Medicine Mathias Lichterfeld, M.D.* Assistant Professor University of California, San Francisco Assistant Professor of Medicine Department of Molecular Biology and Microbiology Veterans Affairs Medical Center Massachusetts General Hospital Case Western Reserve University Jay Rappaport, Ph.D.* Judy Lieberman, M.D., Ph.D. Donna Mildvan, M.D. Professor and Associate Chair Senior Investigator Chief, Division of Infectious Diseases Department of Neuroscience Immune Disease Institute Department of Medicine Temple University Professor of Pediatrics Beth Israel Medical Center Harvard Medical School Lee Ratner, M.D., Ph.D. Jacob Giehm Mikkelsen, Ph.D.* Professor David Looney, M.D.* Professor Department of Medicine Associate Professor of Medicine of Residence Department of Biomedicine Washington University School of Medicine Director, UCSD Center for AIDS Research Aarhus University Molecular Biology Core Roger Keith Reeves, Ph.D.* Medical Director of the San Diego VA Healthcare Avindra Nath, M.D.* Assistant Professor in Medicine System AIDS Care activity Senior Investigator Center for Virology and Vaccine Research Director, Microbiology Laboratory Section of Infections of the Nervous System Beth Israel Deaconess Medical Center VA San Diego Healthcare System National Institute of Neurological Diseases University of California San Diego and Stroke Andrew Rice, Ph.D. National Institutes of Health Professor H. Kim Lyerly, M.D. Department of Molecular Virology Professor in Surgery, Immunology, Pathology Jay A. Nelson, Ph.D. and Microbiology George Barth Geller Chair of Cancer Research Professor and Director Baylor College of Medicine Director of the Center of Applied Therapeutics Vaccine and Gene Therapy Institute Duke Cancer Institute Oregon Health and Science University Melissa Robbiani, Ph.D. Duke University Medical Center Senior Scientist and Director of Biomedical HIV Una O’Doherty, M.D., Ph.D.* Research Rebecca Lynch, Ph.D.* Associate Professor Center for Biomedical Research Assistant Professor Department of Pathology and Laboratory Medicine Population Council School of Medicine and Health Sciences Perelman School of Medicine The George Washington University University of Pennsylvania Fabio Romerio, Ph.D.* Assistant Professor Frank Maldarelli, M.D., Ph.D. Melanie Ott, M.D., Ph.D.* Department of Medicine Investigator Professor Institute of Human Virology HIV DRP Host-Virus Interaction Branch Department of Medicine University of Maryland National Cancer Institute University of California, San Francisco National Institutes of Health

18 Jean-Pierre Routy, M.D.* Gail Skowron, M.D. Thor Wagner, M.D.* Professor Professor of Medicine Assistant Professor Division of Experimental Medicine Boston University School of Medicine Department of Infectious Disease Department of Medicine Seattle Children’s Research Institute McGill University Ole Schmeltz Søgaard, M.D., Ph.D.* Associate Professor Mark Wainberg, Ph.D.* Ruth M. Ruprecht, M.D., Ph.D. Department of Infectious Diseases Professor Scientist, Department of Virology and Immunology Aarhus University Hospital Lady Davis Institute for Medical Research Southwest National Primate Research Center Jewish General Hospital Director, Texas Biomed AIDS Research Program Nikunj Somia, Ph.D.* McGill University Texas Biomedical Research Institute Associate Professor Department of Genetics, Cell Biology, and Marc Weinberg, Ph.D.* Rachel Rutishauser, M.D., Ph.D.* Development Assistant Professor Adjunct Assistant Adjunct Professor College of Biological Sciences Department of Molecular Medicine Department of Medicine University of Minnesota The Scripps Research Institute, California Campus University of California, San Francisco Leonidas Stamatatos, Ph.D. Steven S. Witkin, Ph.D. Jonah Sacha, Ph.D.* Member Professor of Immunology Assistant Professor Fred Hutchinson Cancer Research Center Department of Obstetrics and Gynecology Vaccine and Gene Therapy Institute Vaccine and Infectious Disease Division Weill Cornell Medical College Oregon National Primate Research Center Immunology and Vaccine Development Program Oregon Health and Science University Seattle, WA Peter R. Wolfe, M.D. Associate Clinical Professor Karl Salzwedel, Ph.D.* Kathryn Stephenson, M.D.* David Geffen School of Medicine Chief, Pathogenesis and Basic Research Branch Instructor in Medicine University of California, Los Angeles National Institute of Allergy and Infectious Infectious Disease Division Sub-Investigator Diseases Center for Virology and Vaccine Research Ruane Clinical Research National Institutes of Health Beth Israel Deaconess Medical Center Richard T. Wyatt, Ph.D. Shomyseh Sanjabi, Ph.D.* Mario Stevenson, Ph.D. Professor of Immunology Assistant Investigator Professor of Medicine IAVI Center for Neutralizing Antibodies Gladstone Institute for Virology and Immunology Chief, Division of Infectious Diseases The Scripps Research Institute Gladstone Institute University of Miami Leonard M. Miller School of Medicine Steven Yukl, M.D.* Timothy Schacker, M.D.* Assistant Professor Professor of Medicine Jonathan Stoye, Ph.D.* Department of Medicine Division of Infectious Disease and International Senior Group Leader University of California, San Francisco Medicine Retrovirus-host Interactions Laboratory Department of Medicine The Francis Crick Institute University of Minnesota Semih Tareen, Ph.D.* Frederick A. Schmitt, Ph.D. Director Professor Juno Therapeutics PROGRAM ADVISORY Departments of Neurology, Psychiatry, and Psychology and Behavioral Science Saba Valadkhan, M.D., Ph.D.* COUNCIL Sanders Brown Center on Aging Assistant Professor University of Kentucky Department of Biochemistry Case Western Reserve University Mervyn F. Silverman, M.D., M.P.H. (Chairman) Gerald Schochetman, Ph.D. President Senior Director Susana Valente, Ph.D.* Mervyn F. Silverman Associates Diagnostics Research Associate Professor Crockett, CA Abbott Laboratories Department of Immunology and Microbial Sciences Judith D. Auerbach, Ph.D. Olivier Schwartz, Ph.D.* The Scripps Research Institute Science and Policy Consultant, and Professor Head School of Medicine Department of Virology Barbara Visscher, M.D., Dr.P.H. University of California, San Francisco Institut Pasteur Professor of Epidemiology University of California, Los Angeles David Bloom, Ph.D. Eileen Scully, M.D., Ph.D.* Clarence James Gamble Professor of Economics Assistant Professor of Medicine David Vlahov, Ph.D., R.N. and Demography School of Medicine Professor of Nursing, Department of Global Health and Population Johns Hopkins University Epidemiology, and Biostatistics Harvard T.H. Chan School of Public Health University of California, San Francisco Boston, MA Janet Siliciano, Ph.D.* Associate Professor of Medicine David J. Volsky, Ph.D. Tim Brown, Ph.D. School of Medicine Professor of Medicine and Pathology Senior Fellow Johns Hopkins University Icahn School of Medicine at Mount Sinai The East-West Center Director of Molecular Virology Laboratory Honolulu, HI Guido Silvestri, M.D.* Department of Medicine Professor Mount Sinai St. Luke’s and Roosevelt Hospitals Daniel Douek, M.D., Ph.D. School of Medicine Chief, Human Immunology Section Yerkes National Primate Research Center John Wagner, M.D.* Vaccine Research Center Emory University Executive Medical Director, BMT Program, National Institute of Allergy and Infectious University of Minnesota Masonic Children’s Diseases Viviana Simon, M.D., Ph.D.* Hospital National Institutes of Health Professor of Microbiology and Medicine Professor, Department of Pediatrics Department of Microbiology and Medicine Pediatric Blood & Marrow Transplantation Center Daria J. Hazuda, Ph.D. School of Medicine University of Minnesota Vice President, Scientific Affairs for Infectious Icahn School of Medicine at Mount Sinai Disease Merck & Company, Inc. West Point, PA

19 Katherine Luzuriaga, M.D. Professor, Molecular Medicine, Pediatrics and Medicine University of Massachusetts Medical School Worcester, MA

Kenneth H. Mayer, M.D. Infectious Disease Attending and Director of HIV Prevention Research Beth Israel Deaconess Medical Center

Professor of Medicine Harvard Medical School

Medical Research Director and Co-Chair The Fenway Institute/Fenway Health

Jeffrey L. Sturchio, Ph.D. President and Chief Executive Officer Rabin Martin, NYC

Visiting Scholar The Institute for Applied Economics, Global Health and the Study of Business Enterprise Johns Hopkins University

Member The Council on Foreign Relations

Phill Wilson Chief Executive Officer and President The Black AIDS Institute Los Angeles, CA

MANAGEMENT GROUP

Kevin Robert Frost Chief Executive Officer Anthony Ancona Vice President and Director, Human Resources Susan J. Blumenthal, M.D., M.P.A. Senior Policy and Medical Advisor Bradley Jensen Chief Financial Officer Rowena Johnston, Ph.D. Vice President and Director, Research Jeffrey Laurence, M.D. Senior Scientific Consultant for Programs John F. Logan, Ph.D., J.D. Vice President and General Counsel Gregorio Millett, M.P.H. Vice President and Director, Public Policy Eric Muscatell Vice President, Development AnnMari Shannahan Vice President, Public Information Annette Sohn, M.D. Vice President and Director, TREAT Asia

20 amfAR, The Foundation for AIDS Research

NEW YORK 120 Wall Street, 13th Floor New York, NY 10005-3908 (212) 806-1600 (tel) (212) 806-1601 (fax)

WASHINGTON, D.C. 1100 Vermont Avenue, NW Suite 600 Washington, DC 20005 (202) 331-8600 (tel) (202) 331-8606 (fax)

BANGKOK, THAILAND TREAT Asia Exchange Tower 388 Sukhumvit Road, Suite 2104 Klongtoey, Bangkok 10110 Thailand +66 (0)2 663 7561 (tel) +66 (0)2 663 7562 (fax)

www.amfar.org

amfAR meets the BBB Wise Giving Alliance’s Standards for Charity Accountability.